Rahul Kalla1, Nicholas A Kennedy1, Nicholas T Ventham1, Ray K Boyapati1,2, Alex T Adams1, Elaine R Nimmo1, Micaela R Visconti3, Hazel Drummond1, Gwo-Tzer Ho2, Rebecca J Pattenden4, David C Wilson5, Jack Satsangi1. 1. Gastrointestinal Unit, Centre for Molecular Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK. 2. Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK. 3. Metabolic Bone Unit, Centre for Molecular Medicine, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, UK. 4. Department of Clinical Chemistry, Western General Hospital, NHS Lothian, Edinburgh, UK. 5. Child Life and Health, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK.
Abstract
OBJECTIVES: There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in inflammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. METHODS: A total of 171 patients (n=96 IBD, n=75 non-IBD) were prospectively recruited. A multi-biomarker model was derived using multivariable logistic regression analysis. Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. RESULTS: SC correlated strongly with current biomarkers, including fecal calprotectin (FC) (n=50, ρ=0.50, P=1.6 × 10-4). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 9.37 (95% confidence interval (CI): 2.82-34.68), P=4.00 × 10-4) compared with other markers (C-reactive protein (CRP): OR 8.52 (95% CI: 2.75-28.63), P=2.80 × 10-4); albumin: OR 6.12 (95% CI: 1.82-22.16), P=0.004). In a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic discriminating IBD from controls was better for FC than for SC (0.99, (95% CI 0.87-1.00) and 0.87 (95% CI:0.78-0.97), respectively; P=0.01). At follow-up (median 342 days; interquartile range: 88-563), SC predicted treatment escalation and/or surgery in IBD (hazard ratio (HR) 2.7, 95% CI: 1.1-4.9), in particular Crohn's disease (CD) (HR 4.2, 95% CI 1.2-15.3). A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) in CD if ≥2 blood marker criteria are met. CONCLUSIONS: A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the inflammatory burden in IBD and has the potential to predict disease and its outcomes. Our data warrant further detailed exploration and validation in large multicenter cohorts.
OBJECTIVES: There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in inflammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. METHODS: A total of 171 patients (n=96 IBD, n=75 non-IBD) were prospectively recruited. A multi-biomarker model was derived using multivariable logistic regression analysis. Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. RESULTS: SC correlated strongly with current biomarkers, including fecal calprotectin (FC) (n=50, ρ=0.50, P=1.6 × 10-4). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 9.37 (95% confidence interval (CI): 2.82-34.68), P=4.00 × 10-4) compared with other markers (C-reactive protein (CRP): OR 8.52 (95% CI: 2.75-28.63), P=2.80 × 10-4); albumin: OR 6.12 (95% CI: 1.82-22.16), P=0.004). In a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic discriminating IBD from controls was better for FC than for SC (0.99, (95% CI 0.87-1.00) and 0.87 (95% CI:0.78-0.97), respectively; P=0.01). At follow-up (median 342 days; interquartile range: 88-563), SC predicted treatment escalation and/or surgery in IBD (hazard ratio (HR) 2.7, 95% CI: 1.1-4.9), in particular Crohn's disease (CD) (HR 4.2, 95% CI 1.2-15.3). A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43-79%) and 80% (95% CI: 31-94%) in CD if ≥2 blood marker criteria are met. CONCLUSIONS: A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the inflammatory burden in IBD and has the potential to predict disease and its outcomes. Our data warrant further detailed exploration and validation in large multicenter cohorts.
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein Journal: Gastroenterology Date: 2008-09-17 Impact factor: 22.682
Authors: G T Ho; H M Lee; G Brydon; T Ting; N Hare; H Drummond; A G Shand; D C Bartolo; R G Wilson; M G Dunlop; I D Arnott; J Satsangi Journal: Am J Gastroenterol Date: 2009-02-17 Impact factor: 10.864
Authors: Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Stephan R Vavricka; Lukas E Bruegger; Frank Seibold Journal: Am J Gastroenterol Date: 2009-09-15 Impact factor: 10.864
Authors: James C Lee; Paul A Lyons; Eoin F McKinney; John M Sowerby; Edward J Carr; Francesca Bredin; Hannah M Rickman; Huzefa Ratlamwala; Alexander Hatton; Tim F Rayner; Miles Parkes; Kenneth G C Smith Journal: J Clin Invest Date: 2011-09-26 Impact factor: 14.808
Authors: Nicholas A Kennedy; Annalie Clark; Andrew Walkden; Jeff C W Chang; Federica Fascí-Spurio; Martina Muscat; Brydon W Gordon; Kathleen Kingstone; Jack Satsangi; Ian D R Arnott; Charlie W Lees Journal: J Crohns Colitis Date: 2015-01 Impact factor: 9.071
Authors: Christoph Kessel; Miha Lavric; Toni Weinhage; Markus Brueckner; Sytze de Roock; Jan Däbritz; Jakob Weber; Sebastiaan J Vastert; Dirk Foell Journal: Sci Rep Date: 2021-03-23 Impact factor: 4.379
Authors: R Kalla; A T Adams; D Bergemalm; S Vatn; N A Kennedy; P Ricanek; J Lindstrom; A Ocklind; F Hjelm; N T Ventham; G T Ho; C Petren; D Repsilber; J Söderholm; M Pierik; M D'Amato; F Gomollón; C Olbjorn; J Jahnsen; M H Vatn; J Halfvarson; J Satsangi Journal: J Crohns Colitis Date: 2021-05-04 Impact factor: 10.020
Authors: Rikke Asmussen Andreasen; Lars Erik Kristensen; Torkell Ellingsen; Robin Christensen; Xenofon Baraliakos; Jimmi Wied; Claus Aalykke; Thomas Ulstrup; Berit Schiøttz-Christensen; Hans Christian Horn; Amir Emamifar; Bent Duerlund; Lars Fischer; Inger Marie Jensen Hansen Journal: BMJ Open Date: 2017-07-10 Impact factor: 2.692
Authors: Nathan P Palmer; Jocelyn A Silvester; Jessica J Lee; Andrew L Beam; Inbar Fried; Vladimir I Valtchinov; Fedik Rahimov; Sek Won Kong; Saum Ghodoussipour; Helen C Hood; Athos Bousvaros; Richard J Grand; Louis M Kunkel; Isaac S Kohane Journal: PLoS One Date: 2019-10-16 Impact factor: 3.752
Authors: Judith Zandstra; Annemarie van de Geer; Michael W T Tanck; Diana van Stijn-Bringas Dimitriades; Cathelijn E M Aarts; Sanne M Dietz; Robin van Bruggen; Nina A Schweintzger; Werner Zenz; Marieke Emonts; Dace Zavadska; Marko Pokorn; Effua Usuf; Henriette A Moll; Luregn J Schlapbach; Enitan D Carrol; Stephane Paulus; Maria Tsolia; Colin Fink; Shunmay Yeung; Chisato Shimizu; Adriana Tremoulet; Rachel Galassini; Victoria J Wright; Federico Martinón-Torres; Jethro Herberg; Jane Burns; Michael Levin; Taco W Kuijpers Journal: Front Pediatr Date: 2020-07-22 Impact factor: 3.569